Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 11, 2026

Company name: Fuso Pharmaceutical Industries, Ltd.
Representative: Mikio Toda, President and Representative Director
(Securities code: 4538, Tokyo Stock Exchange Prime Market)
Inquiries: Corporate Communication Office, Corporate Planning Division
(Telephone (main): +81-6-6969-1131)

Notice Concerning Appointment of Executive Officers and Organizational Changes

Fuso Pharmaceutical Industries, Ltd. (the "Company") hereby announces that at a meeting of the Board of Directors held on November 11, 2026, the Company decided on the following appointments for executive officers and organizational changes.

1. Retiring Executive Officer (effective January 1, 2027)

   Satoshi Tanaka (currently Executive Officer, General Manager, Quality & Safety Assurance Div.)

2. Executive Officers Personnel (effective January 1, 2027)

Name	New job title	Current job title
Kazuhisa Iwamoto	Executive Officer, General Manager, Quality & Safety Assurance Div.	Executive Officer, Head of Quality Assurance Dept., Quality & Safety Assurance Div.
Tetsuhiro Maruyama	Executive Officer, Head of Pharmacovigilance Dept., Quality & Safety Assurance Div.	Head of Pharmacovigilance Dept., Quality & Safety Assurance Div.

3. Organizational Changes (effective January 1, 2027)
   The Company will establish Pharmacovigilance Section and Global PV Audit Section within Pharmacovigilance Dept., Quality & Safety Assurance Div.